The Effects of Vasopressin on Attention Control

NCT ID: NCT04493554

Last Updated: 2021-01-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 89 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-28
• Study Completion Date: 2021-01-01

Brief Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) could influence attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Detailed Description

A number of previous studies have reported vasopressin's effect on human social behavior and social cognition, although it remains unclear whether vasopressin could modulate attention allocation including stimulus-driven bottom-up control and goal-directed top-down control. In the current randomized, between-subject, placebo controlled study, 89 healthy male subjects will be recruited and receive either vasopressin (20 IU) or placebo control administered intranasally. 45 minutes after treatment subjects will be required to complete a social-emotional saccade /antisaccade eye-tracking paradigm. The paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of vasopressin.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Vasopressin

Vasopressin (20 IU) intranasally

Group Type: EXPERIMENTAL

Vasopressin

Intervention Type: DRUG

Administration of vasopressin (20 IU) intranasally

Placebo

Placebo intranasally

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Administration of placebo intranasally

Interventions

Vasopressin

Administration of vasopressin (20 IU) intranasally

Intervention Type: DRUG

Placebo

Administration of placebo intranasally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy participants
• Non smokers

Exclusion Criteria

• Previous or current medical, psychiatric, neurological disorder
• Regular medication
• Use of any psychoactive substances in the 24 hours before experiment
• Contra-indications for vasopressin
• Contra-indications for eye-tracking data acquisition

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Keith Kendrick

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Keith Kendrick, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Electronic Science and Technology of China (UESTC)

Locations

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, China

Countries

China

Other Identifiers

UESTC-neuSCAN-70

Identifier Type: -

Identifier Source: org_study_id